Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,554 across all filing types
Latest filing 2021-02-08 Regulatory Filings
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2021 ,inter alia, to consider and approve Dear Sirs, Pursuant to ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about an upcoming Board of Directors meeting scheduled for 23rd February 2021. The purpose of the meeting includes approving audited accounts for the year ended 31st December 2020 and recommending a final dividend. The document is brief (1012 characters) and serves as an announcement rather than containing the actual audited accounts or dividend details. It does not include financial statements or detailed analysis, nor is it a transcript or report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about a board meeting and upcoming report approval, not the report itself or dividend notice.
2021-02-08 English
Updates
Board/Management Information Classification · 95% confidence The document is a letter dated 5th February 2021 from the Company Secretary of Sanofi India Limited addressed to stock exchanges. It announces the Board of Directors' review and approval of a proposed divestment plan related to certain brands. The content focuses on a corporate action (divestment) and the Board's decision, without providing detailed financial data, audit information, or full report content. The document is short (1572 characters) and serves as an official announcement of a Board decision rather than a full report or detailed financial disclosure. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board.
2021-02-05 English
The Board of the Directors of Sanofi India Limited (the Company) at its meeting held today, reviewed the proposed plan of the Sanofi Group to globally sell some of its old brands along ....
Board/Management Information Classification · 95% confidence The document is a letter dated 5th February 2021 from the Company Secretary of Sanofi India Limited addressed to stock exchanges. It announces the Board of Directors' review and approval of a proposed divestment plan for certain brands. The content focuses on a corporate action regarding business divestment and the Board's decision. The document is short (1572 characters) and serves as an official announcement of a Board decision rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a full report, earnings release, or regulatory filing of financial results. The document fits best under Board/Management Information (MANG) as it announces a Board decision related to business strategy and divestment plans.
2021-02-05 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issuance of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, specifically Regulation 39(3). The content is about share certificate replacement and does not contain financial data, earnings, management changes, or report announcements. It is an official regulatory disclosure related to share certificates but does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. The closest fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-02-04 English
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issuance of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, specifically Regulation 39(3). The content is an announcement of a corporate action related to share certificates, not a financial report, earnings release, or management discussion. It does not contain financial data or results, nor is it a report or presentation. This type of announcement fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2021-02-04 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding the loss of share certificates, referencing SEBI regulations. It is an intimation or notification rather than a financial report or detailed filing. The content is brief (1164 characters) and does not contain financial data, management discussion, or regulatory certifications. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like share issue, director dealings, or capital updates.
2021-02-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.